**” Alnylam Pharmaceuticals (ALNY) has experienced notable share price weakness in recent months, trading around $320 with a market cap of approximately $42.5 billion. Despite short-term pressures from market dynamics and profitability revisions, the company’s strong revenue growth trajectory—driven by its TTR franchise and RNAi platform—along with ambitious 2026 guidance and analyst optimism, suggests potential undervaluation relative to long-term prospects. “**
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Recent Share Price Weakness
Alnylam Pharmaceuticals has built a leading position in RNA interference (RNAi) therapeutics, with a commercial portfolio centered on treatments for rare diseases, particularly transthyretin-mediated (ATTR) amyloidosis. The company’s flagship products include AMVUTTRA (vutrisiran) and ONPATTRO (patisiran) for ATTR, alongside GIVLAARI (givosiran) and OXLUMO (lumasiran) for other rare conditions.
Recent share price performance has reflected a pullback, with the stock declining significantly from its all-time highs reached in late 2025. Year-to-date returns show weakness, with drops exceeding 19% in some periods, while longer-term gains remain robust—over 29% in the past year and substantially higher over three and five years. This contrast highlights a shift in near-term investor sentiment amid broader sector volatility and specific company factors.
Key drivers of the recent softness include tempered expectations around the AMVUTTRA launch in ATTR cardiomyopathy, where quarterly growth has moderated due to factors like insurance resets, pricing dynamics, and competitive pressures in the TTR space. Analysts have noted revised downward projections for peak revenues in certain programs, contributing to concerns over future profitability timelines. Gross margins have faced pressure from higher royalties on increased AMVUTTRA sales, and collaboration revenue is expected to decline in the coming year due to one-time milestones passing.
Despite these headwinds, Alnylam’s fundamental story remains compelling. In 2025, the company achieved a transformational milestone by turning profitable on a GAAP basis, reporting full-year net product revenues of nearly $3 billion, representing 81% growth year-over-year. The fourth quarter alone delivered close to $1 billion in net product sales, underscoring robust commercial execution.
Looking forward, management has provided clear 2026 guidance that reinforces confidence in sustained momentum:
Combined net product revenues for AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO: $4.9 billion to $5.3 billion (midpoint implying ~71% growth over 2025).
TTR franchise (AMVUTTRA and ONPATTRO): $4.4 billion to $4.7 billion (midpoint ~83% growth).
Rare disease franchise (GIVLAARI and OXLUMO): $500 million to $600 million (midpoint ~10% growth).
Collaboration and royalty revenue: $400 million to $500 million.
Non-GAAP R&D plus SG&A expenses: $2.7 billion to $2.8 billion.
This guidance reflects optimism around AMVUTTRA’s continued penetration in ATTR-CM, where the product offers differentiated convenience as a subcutaneous quarterly dosing option. While U.S. pricing may see mid-single-digit net declines, volume expansion and global market share gains are expected to drive overall franchise growth.
The pipeline adds further depth to the valuation case. Alnylam is advancing multiple programs, with 2026 milestones including clinical readouts from several candidates, ongoing pivotal studies, new Phase 2 initiations, and potential IND filings. Expansion into larger indications—such as Huntington’s disease, obesity, and hereditary hemorrhagic telangiectasia (HHT)—could unlock significant additional value beyond the core rare disease focus.
Valuation metrics present a mixed but intriguing picture. The trailing P/E ratio sits elevated at over 137, reflecting the company’s recent profitability inflection and growth profile. Forward P/E estimates are more reasonable, in the mid-30s, aligning with high-growth biotech peers. Market capitalization hovers around $42.5 billion, with enterprise value slightly lower accounting for cash balances.
Analyst consensus remains bullish, with average price targets clustered in the $450-$480 range (implying substantial upside from current levels near $320). Ratings lean toward Buy or Outperform, with some firms maintaining high conviction despite recent target trims tied to near-term dynamics. Certain discounted cash flow models suggest the stock trades at a meaningful discount—potentially 30-50%—to intrinsic value estimates that incorporate long-term RNAi platform potential and revenue compounding.
Key Valuation Considerations
Strengths Supporting Higher Valuation — Proven commercial ramp in TTR, first-mover advantages in RNAi, pipeline diversification, and path to operating margins exceeding 30% by 2030 under long-term targets of >25% revenue CAGR.
Risks Weighing on Near-Term Sentiment — Execution challenges in competitive landscapes, pricing headwinds, R&D spend intensity, and dependence on TTR franchise for near-term growth.
Comparative Metrics — Price-to-sales ratio around 11-12x trailing revenues, which is premium but justifiable given projected growth acceleration.
Overall, the recent weakness appears to have created a potential entry point for investors focused on Alnylam’s multi-year growth story. The combination of reaffirmed ambitious guidance, profitability achievement, and pipeline catalysts positions the company to potentially rebound as market focus shifts from short-term pressures to sustained execution.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial recommendations, or an offer to buy or sell securities. Investing in stocks involves significant risk, including potential loss of principal.
